JP2019527728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019527728A5 JP2019527728A5 JP2019522611A JP2019522611A JP2019527728A5 JP 2019527728 A5 JP2019527728 A5 JP 2019527728A5 JP 2019522611 A JP2019522611 A JP 2019522611A JP 2019522611 A JP2019522611 A JP 2019522611A JP 2019527728 A5 JP2019527728 A5 JP 2019527728A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutically acceptable
- compound
- tautomer
- solvate
- isomer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 7
- 239000011780 sodium chloride Substances 0.000 claims 7
- 239000012453 solvate Substances 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 1
- 210000000481 Breast Anatomy 0.000 claims 1
- 210000001072 Colon Anatomy 0.000 claims 1
- 208000005101 LEOPARD Syndrome Diseases 0.000 claims 1
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 1
- 208000002490 Leukemia, Myelomonocytic, Juvenile Diseases 0.000 claims 1
- 210000004072 Lung Anatomy 0.000 claims 1
- 206010025650 Malignant melanoma Diseases 0.000 claims 1
- 206010062901 Multiple lentigines syndrome Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010029748 Noonan syndrome Diseases 0.000 claims 1
- 102100017818 PTPN11 Human genes 0.000 claims 1
- 101710018405 PTPN11 Proteins 0.000 claims 1
- 101700028234 agl5 Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 201000005992 juvenile myelomonocytic leukemia Diseases 0.000 claims 1
- 201000001441 melanoma Diseases 0.000 claims 1
- 230000000051 modifying Effects 0.000 claims 1
- 0 C*(C)CC[C@@]1OCC(CC2)(CCN2c(nc2C)c(CO)nc2Sc2cccc(Cl)c2Cl)[C@@]1N Chemical compound C*(C)CC[C@@]1OCC(CC2)(CCN2c(nc2C)c(CO)nc2Sc2cccc(Cl)c2Cl)[C@@]1N 0.000 description 1
Claims (9)
-
- 化合物が：
- 化合物が：
- 化合物が：
- 化合物が：
- 化合物が：
- 請求項１〜６のいずれか１項に記載の化合物、またはその薬学的に許容される塩、溶媒和物、水和物、互変異性体もしくは異性体、および薬学的に許容される担体を含む医薬組成物。
- それを必要とする対象におけるＳＨＰ２モジュレーションに関連する疾患を処置する方法で使用するための請求項７に記載の医薬組成物であって、前記方法は、有効量の医薬組成物を対象に投与することを含む、上記医薬組成物。
- 疾患は、ヌーナン症候群、レオパード症候群、若年性骨髄単球性白血病、神経芽細胞腫、メラノーマ、急性骨髄球性白血病、ならびに乳房、肺および結腸のがんから選択される、請求項８に記載の医薬組成物。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021116788A JP7416740B2 (ja) | 2016-07-12 | 2021-07-15 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
| JP2023177195A JP2024009957A (ja) | 2016-07-12 | 2023-10-13 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662361249P | 2016-07-12 | 2016-07-12 | |
| US62/361,249 | 2016-07-12 | ||
| US201762449523P | 2017-01-23 | 2017-01-23 | |
| US62/449,523 | 2017-01-23 | ||
| PCT/US2017/041577 WO2018013597A1 (en) | 2016-07-12 | 2017-07-11 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021116788A Division JP7416740B2 (ja) | 2016-07-12 | 2021-07-15 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019527728A JP2019527728A (ja) | 2019-10-03 |
| JP2019527728A5 true JP2019527728A5 (ja) | 2021-07-26 |
| JP6916279B2 JP6916279B2 (ja) | 2021-08-11 |
Family
ID=59383648
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019522611A Active JP6916279B2 (ja) | 2016-07-12 | 2017-07-11 | アロステリックｓｈｐ２阻害剤としての２，５−二置換３−メチルピラジンおよび２，５，６−三置換３−メチルピラジン |
| JP2021116788A Active JP7416740B2 (ja) | 2016-07-12 | 2021-07-15 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
| JP2023177195A Pending JP2024009957A (ja) | 2016-07-12 | 2023-10-13 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021116788A Active JP7416740B2 (ja) | 2016-07-12 | 2021-07-15 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
| JP2023177195A Pending JP2024009957A (ja) | 2016-07-12 | 2023-10-13 | アロステリックｓｈｐ２阻害剤としての２，５－二置換３－メチルピラジンおよび２，５，６－三置換３－メチルピラジン |
Country Status (22)
| Country | Link |
|---|---|
| US (3) | US10590090B2 (ja) |
| EP (2) | EP3484856B1 (ja) |
| JP (3) | JP6916279B2 (ja) |
| KR (2) | KR20230156174A (ja) |
| CN (3) | CN116478132A (ja) |
| AU (3) | AU2017296289A1 (ja) |
| BR (1) | BR112019000494A2 (ja) |
| CA (1) | CA3030167A1 (ja) |
| CL (1) | CL2019000090A1 (ja) |
| CO (1) | CO2019000613A2 (ja) |
| CR (1) | CR20190063A (ja) |
| DO (1) | DOP2019000005A (ja) |
| EC (1) | ECSP19010079A (ja) |
| IL (2) | IL311645A (ja) |
| MA (1) | MA45660A (ja) |
| MX (2) | MX2019000548A (ja) |
| PE (1) | PE20190624A1 (ja) |
| PH (1) | PH12019500056A1 (ja) |
| SG (1) | SG11201900157RA (ja) |
| TN (1) | TN2019000010A1 (ja) |
| TW (2) | TWI806832B (ja) |
| WO (1) | WO2018013597A1 (ja) |
Families Citing this family (115)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11466017B2 (en) | 2011-03-10 | 2022-10-11 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| US10280171B2 (en) | 2016-05-31 | 2019-05-07 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| TWI806832B (zh) | 2016-07-12 | 2023-07-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| US10988466B2 (en) * | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| CA3074304A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| RU2020115095A (ru) | 2017-10-12 | 2021-11-12 | Революшн Медсинз, Инк. | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| CN110655520A (zh) * | 2018-06-29 | 2020-01-07 | 上海青煜医药科技有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| CN110156786B (zh) * | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| MA51845A (fr) * | 2018-02-13 | 2020-12-23 | Shanghai Blueray Biopharma Co Ltd | Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application |
| SG11202009245TA (en) * | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| TW201940167A (zh) * | 2018-03-21 | 2019-10-16 | 美商新標利亞治療藥物公司 | Shp2抑制劑及其用途 |
| JP2021521155A (ja) * | 2018-04-10 | 2021-08-26 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法 |
| US10954243B2 (en) * | 2018-05-02 | 2021-03-23 | Navire Pharma, Inc. | Substituted heterocyclic inhibitors of PTPN11 |
| IL280701B2 (en) | 2018-08-10 | 2024-03-01 | Navire Pharma Inc | History of 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(3,2-dichlorophenyl)-2-methylpyrimidin-4(H3)-one and compounds associated as PTPN11 (SHP2) inhibitors for cancer treatment |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| WO2020063760A1 (en) * | 2018-09-26 | 2020-04-02 | Jacobio Pharmaceuticals Co., Ltd. | Novel heterocyclic derivatives useful as shp2 inhibitors |
| KR20210068472A (ko) * | 2018-09-29 | 2021-06-09 | 노파르티스 아게 | Shp2 활성의 억제를 위한 화합물 및 조성물의 제조 |
| US11179397B2 (en) | 2018-10-03 | 2021-11-23 | Gilead Sciences, Inc. | Imidazopyrimidine derivatives |
| CN113473990A (zh) * | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
| TW202028183A (zh) * | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
| JP7449282B2 (ja) | 2018-10-17 | 2024-03-13 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害薬 |
| CN109265352B (zh) * | 2018-10-31 | 2021-06-04 | 杭州迈世腾药物科技有限公司 | 芳基环丙基醚及其衍生物的制备方法 |
| CN113272303B (zh) | 2018-11-30 | 2024-09-17 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| CN113316574B (zh) * | 2019-01-31 | 2024-01-30 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| CN113727758A (zh) | 2019-03-01 | 2021-11-30 | 锐新医药公司 | 双环杂环基化合物及其用途 |
| KR20210146287A (ko) | 2019-03-01 | 2021-12-03 | 레볼루션 메디슨즈, 인크. | 이환식 헤테로아릴 화합물 및 이의 용도 |
| CN111647000B (zh) * | 2019-03-04 | 2021-10-12 | 勤浩医药（苏州）有限公司 | 吡嗪类衍生物及其在抑制shp2中的应用 |
| AU2020232026A1 (en) | 2019-03-07 | 2021-09-02 | Merck Patent Gmbh | Carboxamide-pyrimidine derivatives as shp2 antagonists |
| JP7284830B2 (ja) | 2019-04-02 | 2023-05-31 | アレイ バイオファーマ インコーポレイテッド | タンパク質チロシンホスファターゼ阻害剤 |
| US11001561B2 (en) | 2019-04-08 | 2021-05-11 | Merck Patent Gmbh | Pyrimidinone derivatives as SHP2 antagonists |
| EP3980128A1 (en) | 2019-06-07 | 2022-04-13 | Revolution Medicines, Inc. | Solid forms of {6-[(2-amino-3-chloropyridin-4-yl)sulfanyl]-3-[(3s,4s)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl]-5-methylpyrazin-2-yl}methanol, an shp2 inhibitor |
| WO2020259679A1 (zh) | 2019-06-28 | 2020-12-30 | 上海拓界生物医药科技有限公司 | 嘧啶并五元氮杂环类衍生物、其制备方法及其在医药上的应用 |
| CN111704611B (zh) * | 2019-07-25 | 2022-01-14 | 上海凌达生物医药有限公司 | 一类芳基螺环类shp2抑制剂化合物、制备方法和用途 |
| CN112300160A (zh) * | 2019-08-01 | 2021-02-02 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物、其制备及应用 |
| EP3772513A1 (en) | 2019-08-09 | 2021-02-10 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | Shp2 inhibitors |
| CN114127053B (zh) * | 2019-09-06 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
| US20230010886A1 (en) * | 2019-09-23 | 2023-01-12 | Suzhou Puhe BioPharma Co., Ltd. | Shp2 inhibitors and uses thereof |
| AR120082A1 (es) | 2019-09-24 | 2022-02-02 | Relay Therapeutics Inc | Inhibidores de fosfatasa shp-2 y métodos para fabricarlos y usarlos |
| CN112724145A (zh) * | 2019-10-14 | 2021-04-30 | 杭州雷索药业有限公司 | 用于抑制shp2活性的吡嗪衍生物 |
| US20240139193A1 (en) | 2019-10-15 | 2024-05-02 | Amgen Inc. | Combination therapy of kras inhibitor and shp2 inhibitor for treatment of cancers |
| KR20220109407A (ko) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | Ras 억제제 |
| AU2020379734A1 (en) | 2019-11-04 | 2022-05-05 | Revolution Medicines, Inc. | Ras inhibitors |
| CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
| MX2022005525A (es) | 2019-11-08 | 2022-06-08 | Revolution Medicines Inc | Compuestos de heteroarilo bicíclicos y usos de estos. |
| EP4065231A1 (en) | 2019-11-27 | 2022-10-05 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| EP4069301A1 (en) | 2019-12-04 | 2022-10-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
| AU2021206217A1 (en) | 2020-01-07 | 2022-09-01 | Revolution Medicines, Inc. | SHP2 inhibitor dosing and methods of treating cancer |
| CN114867720B (zh) | 2020-01-16 | 2024-10-22 | 浙江海正药业股份有限公司 | 杂芳基类衍生物及其制备方法和用途 |
| CN113135910A (zh) | 2020-01-19 | 2021-07-20 | 北京诺诚健华医药科技有限公司 | 嘧啶-4(3h)-酮类杂环化合物、其制备方法及其在医药学上的应用 |
| CN114846005B (zh) * | 2020-01-21 | 2024-04-02 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| EP4110338A1 (en) | 2020-02-28 | 2023-01-04 | Novartis AG | A triple pharmaceutical combination comprising dabrafenib, an erk inhibitor and a shp2 inhibitor |
| CN113493440B (zh) * | 2020-04-03 | 2024-08-23 | 上海翰森生物医药科技有限公司 | 含氮杂芳类衍生物的盐及其晶型 |
| TW202144334A (zh) * | 2020-04-03 | 2021-12-01 | 大陸商上海翰森生物醫藥科技有限公司 | 含氮雜芳類衍生物游離鹼的晶型 |
| CN115362149B (zh) * | 2020-04-26 | 2024-05-14 | 贝达药业股份有限公司 | Shp2抑制剂及其组合物和应用 |
| TW202214636A (zh) * | 2020-06-11 | 2022-04-16 | 大陸商貝達藥業股份有限公司 | Ｓｈｐ２抑制劑及其組合物和應用 |
| AU2021293228A1 (en) | 2020-06-18 | 2023-02-09 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to RAS inhibitors |
| WO2021259077A1 (zh) | 2020-06-22 | 2021-12-30 | 四川科伦博泰生物医药股份有限公司 | 取代吡嗪类化合物，包含其的药物组合物及其用途 |
| CN116113418A (zh) * | 2020-08-25 | 2023-05-12 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| JP2023541916A (ja) | 2020-09-15 | 2023-10-04 | レボリューション メディシンズ インコーポレイテッド | がんの治療における、ｒａｓ阻害剤としてのインドール誘導体 |
| AU2021370660A1 (en) | 2020-10-27 | 2023-06-08 | Amgen Inc. | Heterocyclic spiro compounds and methods of use |
| CA3202424A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| CN116568308A (zh) * | 2021-01-29 | 2023-08-08 | 四川科伦博泰生物医药股份有限公司 | 一类杂环类shp2抑制剂、其制备方法及用途 |
| EP4039685A1 (en) | 2021-02-08 | 2022-08-10 | Irbm S.P.A. | Azabicyclic shp2 inhibitors |
| WO2022206684A1 (zh) * | 2021-03-31 | 2022-10-06 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| EP4067358A1 (en) | 2021-04-02 | 2022-10-05 | C.N.C.C.S. S.c.a.r.l. Collezione Nazionale Dei Composti Chimici e Centro Screening | (s)-1-(5-((pyridin-3-yl)thio)pyrazin-2-yl)-4'h,6'h-spiro[piperidine-4,5'-pyrrolo[1,2-b]pyrazol]-4'-amine derivatives and similar compounds as shp2 inhibitors for the treatment of e.g. cancer |
| JP2024517693A (ja) | 2021-04-29 | 2024-04-23 | アムジエン・インコーポレーテツド | ２－アミノベンゾチアゾール化合物及びその使用方法 |
| EP4333847A1 (en) | 2021-05-05 | 2024-03-13 | Novartis AG | Compounds and compositions for the treatment of mpnst |
| CN117616031A (zh) | 2021-05-05 | 2024-02-27 | 锐新医药公司 | 用于治疗癌症的ras抑制剂 |
| JP2024517847A (ja) | 2021-05-05 | 2024-04-23 | レボリューション メディシンズ インコーポレイテッド | Ｒａｓ阻害剤 |
| JP2024516450A (ja) | 2021-05-05 | 2024-04-15 | レボリューション メディシンズ インコーポレイテッド | 共有結合性ｒａｓ阻害剤及びその使用 |
| US12097203B2 (en) | 2021-05-05 | 2024-09-24 | Huyabio International, Llc | Combination therapies comprising SHP2 inhibitors and PD-1 inhibitors |
| CA3217097A1 (en) * | 2021-05-05 | 2022-11-10 | Huyabio International, Llc | Shp2 inhibitor monotherapy and uses thereof |
| WO2022237367A1 (zh) * | 2021-05-13 | 2022-11-17 | 中国科学院上海药物研究所 | 抑制shp2活性的杂环化合物、其制备方法及用途 |
| EP4342891A1 (en) | 2021-05-21 | 2024-03-27 | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. | Spiro compound and use thereof |
| WO2022259157A1 (en) | 2021-06-09 | 2022-12-15 | Novartis Ag | A triple pharmaceutical combination comprising dabrafenib, trametinib and a shp2 inhibitor |
| TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含ｋｒａｓ ｇ１２ｃ抑制劑的藥物組合及其用於治療癌症之用途 |
| KR102682323B1 (ko) * | 2021-07-09 | 2024-07-09 | 주식회사 카나프테라퓨틱스 | Shp2 억제제 및 이의 용도 |
| CN113636952B (zh) * | 2021-07-19 | 2023-07-21 | 河南农业大学 | 一种制备4-溴苯甲酰胺的方法 |
| CN117881678A (zh) * | 2021-08-09 | 2024-04-12 | 尤比克斯治疗公司 | 具有shp2蛋白降解活性的化合物及其医学用途 |
| KR20240055778A (ko) | 2021-09-01 | 2024-04-29 | 노파르티스 아게 | Tead 억제제를 포함하는 제약 조합물 및 암의 치료를 위한 이의 용도 |
| CN116323566B (zh) * | 2021-09-27 | 2024-05-17 | 中国医药研究开发中心有限公司 | 磺胺酮类化合物及其制备方法和医药用途 |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN118401505A (zh) * | 2021-12-28 | 2024-07-26 | 捷思英达控股有限公司 | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物及其使用方法 |
| WO2023159086A1 (en) | 2022-02-16 | 2023-08-24 | Amgen Inc. | Quinazoline compounds and use thereof as inhibtors of mutant kras proteins |
| CN118715215A (zh) | 2022-02-16 | 2024-09-27 | 美国安进公司 | 作为突变kras蛋白抑制剂的喹唑啉化合物及其用途 |
| WO2023168036A1 (en) | 2022-03-04 | 2023-09-07 | Eli Lilly And Company | Method of treatment including kras g12c inhibitors and shp2 inhibitors |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN118369323A (zh) * | 2022-03-10 | 2024-07-19 | 捷思英达控股有限公司 | 作为shp2抑制剂的杂环化合物、包括该杂环化合物的组合物、及其使用方法 |
| WO2023180245A1 (en) | 2022-03-21 | 2023-09-28 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of shp2 inhibitors for inhibiting senescence |
| CN118871443A (zh) * | 2022-03-28 | 2024-10-29 | 建新公司 | 用于制备shp2抑制剂的方法 |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024015360A1 (en) | 2022-07-11 | 2024-01-18 | Amgen Inc. | Methods of treating cancer |
| WO2024040131A1 (en) | 2022-08-17 | 2024-02-22 | Treeline Biosciences, Inc. | Pyridopyrimidine kras inhibitors |
| EP4345101A1 (en) | 2022-09-29 | 2024-04-03 | Irbm S.P.A. | Azole derivatives as shp2 inhibitors |
| WO2024085699A1 (ko) * | 2022-10-19 | 2024-04-25 | 주식회사 유빅스테라퓨틱스 | Shp2 단백질 분해용 화합물 및 이들의 의약 용도 |
| WO2024113194A1 (en) * | 2022-11-30 | 2024-06-06 | Canwell Biotech Limited | Shp2 inhibitors, compositions and methods thereof |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024211712A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| WO2024211663A1 (en) | 2023-04-07 | 2024-10-10 | Revolution Medicines, Inc. | Condensed macrocyclic compounds as ras inhibitors |
| US20240352038A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| US20240352036A1 (en) | 2023-04-14 | 2024-10-24 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
Family Cites Families (123)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2572728A (en) * | 1949-01-07 | 1951-10-23 | American Cyanamid Co | Hydroxybenzenesulfonamidopyra-zines and preparation of same |
| US2636882A (en) | 1950-08-11 | 1953-04-28 | Quaker Oats Co | Preparation of 3-pyridols from 2-acylfurans |
| BE758503A (fr) | 1969-11-07 | 1971-05-05 | Shell Int Research | Compositions pesticides |
| GB1459571A (en) | 1974-09-12 | 1976-12-22 | Pfizer Ltd | Thiophene-2-sulphonamide derivatives and their use as therapeutic agents sheet orienting apparatus |
| JPS5762269A (en) * | 1980-10-03 | 1982-04-15 | Ogawa Koryo Kk | 2,3,5-trisubstituted pyrazine derivative |
| US4513135A (en) * | 1982-03-05 | 1985-04-23 | Eli Lilly And Company | Diaryl-pyrazine derivatives affecting GABA binding |
| JPH0249775A (ja) | 1988-05-19 | 1990-02-20 | Nippon Soda Co Ltd | ６員環又は７員環を有する複素環化合物及びその製造方法 |
| JPH04112877A (ja) | 1990-09-04 | 1992-04-14 | Nippon Soda Co Ltd | 新規シアノピラジン誘導体及びその製造方法 |
| EP0579835A4 (en) | 1991-11-12 | 1994-06-01 | Nippon Soda Co | Wavelength conversion material for agriculture |
| US5262564A (en) | 1992-10-30 | 1993-11-16 | Octamer, Inc. | Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents |
| GB9504854D0 (en) * | 1994-03-31 | 1995-04-26 | Zeneca Ltd | Nitrogen derivatives |
| ES2168237T3 (es) | 1996-02-07 | 2007-04-01 | Neurocrine Biosciences, Inc. | Pirazolopirimidinas como antagonistas de receptores de crf. |
| AU8071698A (en) * | 1997-06-13 | 1998-12-30 | Sugen, Inc. | Novel heteroaryl compounds for the modulation of protein tyrosine enzyme relatedcellular signal transduction |
| JP2003508382A (ja) | 1999-08-27 | 2003-03-04 | スージェン・インコーポレーテッド | リン酸模倣体およびホスファターゼ阻害剤を用いる治療方法 |
| ATE307121T1 (de) | 2000-02-16 | 2005-11-15 | Neurogen Corp | Substituierte arylpyrazine |
| CA2495529C (en) | 2001-10-01 | 2009-05-19 | Mount Sinai School Of Medicine Of New York University | Noonan syndrome gene |
| US6921762B2 (en) | 2001-11-16 | 2005-07-26 | Amgen Inc. | Substituted indolizine-like compounds and methods of use |
| AU2002343557A1 (en) | 2001-11-21 | 2003-06-10 | Pharmacia And Upjohn Company | Substituted aryl 1,4-pyrazine derivatives |
| JP2005531520A (ja) | 2002-03-28 | 2005-10-20 | メルク エンド カムパニー インコーポレーテッド | 置換２，３−ジフェニルピリジン類 |
| WO2004024719A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmacia & Upjohn Company Llc | Substituted 1,4-pyrazine derivatives |
| ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
| US7157460B2 (en) | 2003-02-20 | 2007-01-02 | Sugen Inc. | Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors |
| CA2524519A1 (en) | 2003-05-09 | 2004-11-18 | Pharmacia & Upjohn Company Llc | Compounds as crf1 receptor antagonists |
| GB0314057D0 (en) * | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| FR2856684B1 (fr) | 2003-06-26 | 2008-04-11 | Sanofi Synthelabo | Derives de diphenylpyridine, leur preparation et leur application en therapeutique |
| US7326706B2 (en) * | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
| CA2537916A1 (en) | 2003-09-03 | 2005-03-31 | Neurogen Corporation | 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds |
| US7709473B2 (en) | 2003-10-10 | 2010-05-04 | Pfizer Inc. | Substituted 2H-[1,2,4]triazolo[4,3-a]pyrazines as GSK-3 inhibitors |
| EP1678160A1 (en) * | 2003-10-27 | 2006-07-12 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof |
| DE102004015954A1 (de) * | 2004-04-01 | 2005-11-10 | Ina-Schaeffler Kg | Umschlingungstrieb |
| WO2005095384A1 (en) * | 2004-04-01 | 2005-10-13 | Astellas Pharma Inc. | Pyrazine derivatives and pharmaceutical use thereof as adenosine antagonists |
| EP1758873A1 (en) | 2004-06-22 | 2007-03-07 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
| CA2592021A1 (en) | 2004-12-23 | 2006-07-06 | Raghavan Rajagopalan | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function |
| WO2006113704A2 (en) * | 2005-04-18 | 2006-10-26 | Neurogen Corporation | Subtituted heteroaryl cb1 antagonists |
| EP3088400A1 (en) | 2005-06-22 | 2016-11-02 | Plexxikon Inc. | Pyrrolo[2,3-b]pyridine derivatives as protein kinase inhibitors |
| EP3061834B1 (en) | 2005-10-21 | 2020-01-08 | The Regents of the University of California | Shp-2 gene mutations in melanoma |
| WO2007106142A2 (en) | 2006-02-24 | 2007-09-20 | Mallinckrodt Inc. | Process for using optical agents |
| WO2007117699A2 (en) | 2006-04-07 | 2007-10-18 | University Of South Florida | Inhibition of shp2/ptpn11 protein tyrosine phosphatase by nsc-87877, nsc-117199 and their analogs |
| AU2007243280A1 (en) | 2006-04-28 | 2007-11-08 | Northwestern University | Formulations containing pyridazine compounds for treating neuroinflammatory diseases |
| US7893058B2 (en) | 2006-05-15 | 2011-02-22 | Janssen Pharmaceutica Nv | Imidazolopyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| DK2029602T3 (da) | 2006-05-31 | 2010-08-09 | Galapagos Nv | Triazolopyrazinforbindelser, der kan anvendes til behandling af degenerative og inflammatoriske sygdomme |
| WO2007145921A1 (en) | 2006-06-06 | 2007-12-21 | Schering Corporation | Imidazopyrazines as protein kinase inhibitors |
| JP2010520238A (ja) * | 2007-03-01 | 2010-06-10 | マリンクロット インコーポレイテッド | 統合された光活性低分子および統合された光活性低分子使用 |
| JP2010523530A (ja) | 2007-04-06 | 2010-07-15 | ノバルティス アーゲー | タンパク質キナーゼ阻害剤として有益な［２，６］ナフチリジン |
| US8133895B2 (en) | 2007-05-10 | 2012-03-13 | Janssen Pharmaceutica N.V. | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US8148369B2 (en) | 2007-05-10 | 2012-04-03 | Janssen Pharmaceutica Nv | Fused pyrazine compounds useful for the treatment of degenerative and inflammatory diseases |
| US20100190980A1 (en) | 2007-06-21 | 2010-07-29 | Taisho Pharmaceutical Co., Ltd | Pyrazinamide compound |
| AU2008284268A1 (en) | 2007-08-09 | 2009-02-12 | Merck & Co., Inc. | Pyridine carboxamide orexin receptor antagonists |
| US20090062277A1 (en) | 2007-08-21 | 2009-03-05 | Essa Hu | Phosphodiesterase 10 inhibitors |
| JP2010031249A (ja) * | 2008-06-23 | 2010-02-12 | Sumitomo Chemical Co Ltd | 組成物及び該組成物を用いてなる発光素子 |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| CA2741649A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Pyridazine carboxamide orexin receptor antagonists |
| US8846664B2 (en) * | 2008-11-12 | 2014-09-30 | Ariad Pharmaceuticals, Inc. | Pyrazinopyrazines and derivatives as kinase inhibitors |
| PT2565193E (pt) | 2009-01-23 | 2014-06-05 | Rigel Pharmaceuticals Inc | Composições e métodos para a inibição da via jak |
| WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
| US20120065205A1 (en) | 2009-06-01 | 2012-03-15 | Mercer Swati P | Pyrazine carboxamide orexin receptor antagonists |
| BR112012003637A2 (pt) * | 2009-08-17 | 2017-04-25 | Memorial Sloan Kettering Cancer Center | "compostos de ligação de proteína de choque térmico, composições, e métodos para preparar e usar os mesmos" |
| EP2473530B1 (en) | 2009-09-03 | 2015-04-22 | Vancouver Biotech Ltd. | Monoclonal antibodies against gonadotropin-releasing hormone receptor |
| US8673913B2 (en) | 2009-11-13 | 2014-03-18 | Case Western Reserve University | SHP-2 phosphatase inhibitor |
| WO2011131407A1 (en) | 2010-03-05 | 2011-10-27 | F. Hoffmann-La Roche Ag | Antibodies against human csf-1r and uses thereof |
| WO2011143148A1 (en) | 2010-05-11 | 2011-11-17 | Sanofi | Substituted n-heteroaryl spirolactam bipyrrolidines, preparation and therapeutic use thereof |
| US8703768B2 (en) * | 2010-06-09 | 2014-04-22 | Hoffmann-La Roche Inc. | Nitrogen containing heteroaryl compounds |
| KR101491938B1 (ko) * | 2010-07-14 | 2015-02-10 | 노파르티스 아게 | Ｉｐ 수용체 효능제 헤테로시클릭 화합물 |
| GB201106829D0 (en) * | 2011-04-21 | 2011-06-01 | Proximagen Ltd | Heterocyclic compounds |
| JP5808826B2 (ja) | 2011-02-23 | 2015-11-10 | インテリカイン， エルエルシー | 複素環化合物およびその使用 |
| US20120330012A1 (en) | 2011-04-29 | 2012-12-27 | Abbott Laboratories | Novel Tricyclic Compounds |
| CN103181918B (zh) | 2011-05-04 | 2014-10-29 | 厦门大学 | 脂肪酸类化合物在制备预防和治疗肝癌药物中的应用 |
| EP2802583A1 (en) * | 2012-01-13 | 2014-11-19 | Novartis AG | Fused piperidines as ip receptor agonists for the treatment of pulmonary arterial hypertension (pah) and related disorders |
| EP2805940B1 (en) * | 2012-01-17 | 2016-11-23 | Astellas Pharma Inc. | Pyrazine carboxamide compound |
| ES2618004T3 (es) | 2012-08-07 | 2017-06-20 | Merck Patent Gmbh | Derivados de piridopirimidina como inhibidores de proteínas quinasas |
| RU2617842C2 (ru) | 2012-11-08 | 2017-04-28 | Пфайзер Инк. | Гетероароматические соединения и их применение в качестве допаминовых D1 лигандов |
| AU2013352304C1 (en) | 2012-11-29 | 2018-03-22 | Chemocentryx, Inc. | CXCR7 antagonists |
| WO2014113584A1 (en) | 2013-01-16 | 2014-07-24 | Rhode Island Hospital | Compositions and methods for the prevention and treatment of osteolysis and osteoporosis |
| JP2016507538A (ja) * | 2013-02-07 | 2016-03-10 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 置換キノキサリン誘導体およびｍＧｌｕＲ４の正のアロステリックモジュレーターとしてのそれらの使用 |
| US9394368B2 (en) | 2013-02-20 | 2016-07-19 | Novartis Ag | Treatment of cancer using humanized anti-EGFRvIII chimeric antigen receptor |
| BR112015022260B1 (pt) | 2013-03-13 | 2023-05-16 | Prothena Biosciences Limited | Anticorpo monoclonal que se liga ao tau, polinucleotídeo, composição farmacêutica e uso de um anticorpo |
| CN103554038B (zh) | 2013-06-19 | 2015-10-14 | 云南大学 | 多卤代苯腈喹唑啉酮化合物及其制备方法和用途 |
| JO3517B1 (ar) * | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| EP3094629B1 (en) * | 2014-01-17 | 2018-08-22 | Novartis AG | 1-(triazin-3-yl/pyridazin-3-yl)-piper(-azine)idine derivatives and compositions thereof for inhibiting the activity of shp2 |
| WO2015107493A1 (en) * | 2014-01-17 | 2015-07-23 | Novartis Ag | 1 -pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and and compositions thereof for inhibiting the activity of shp2 |
| WO2016007731A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Imidazopyridines and imidazopyrazines as lsd1 inhibitors |
| RU2743074C2 (ru) | 2014-08-01 | 2021-02-15 | Нуэволюшон А/С | Соединения, активные по отношению к бромодоменам |
| CA2960188A1 (en) * | 2014-09-05 | 2016-03-10 | Celgene Quanticel Research, Inc. | Inhibitors of lysine specific demethylase-1 |
| CN107106558A (zh) * | 2014-11-18 | 2017-08-29 | 默沙东公司 | 具有a2a拮抗剂性质的氨基吡嗪化合物 |
| ES2881305T3 (es) | 2014-12-17 | 2021-11-29 | Siemens Healthcare Diagnostics Inc | Diseño de ensayo sandwich para pequeñas moléculas |
| EP3237418B1 (en) | 2014-12-23 | 2019-01-30 | Novartis AG | Triazolopyrimidine compounds and uses thereof |
| EP3247378B8 (en) | 2015-01-09 | 2023-08-23 | Revolution Medicines, Inc. | Macrocyclic compounds that participate in cooperative binding and medical uses thereof |
| WO2016144936A1 (en) * | 2015-03-09 | 2016-09-15 | Bristol-Myers Squibb Company | Lactams as inhibitors of rock |
| NZ735998A (en) | 2015-04-03 | 2024-08-30 | Incyte Holdings Corp | Heterocyclic compounds as lsd1 inhibitors |
| US10975080B2 (en) | 2015-06-19 | 2021-04-13 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| US10308660B2 (en) | 2015-06-19 | 2019-06-04 | Novartis Ag | Compounds and compositions for inhibiting the activity of SHP2 |
| JP6718889B2 (ja) * | 2015-06-19 | 2020-07-08 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物および組成物 |
| WO2017011618A1 (en) | 2015-07-15 | 2017-01-19 | The Curators Of The University Of Missouri | Targeted nanoparticle conjugate and method for co-delivery of sirna and drug |
| EP4242304A3 (en) | 2015-10-01 | 2024-02-07 | Revolution Medicines, Inc. | Methods and reagents for analyzing protein-protein interfaces |
| WO2017079723A1 (en) | 2015-11-07 | 2017-05-11 | Board Of Regents, The University Of Texas System | Targeting proteins for degradation |
| WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
| KR20230109185A (ko) * | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| TWI806832B (zh) | 2016-07-12 | 2023-07-01 | 美商銳新醫藥公司 | 作為異位shp2抑制劑之2,5-雙取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
| WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| TWI848901B (zh) | 2016-10-24 | 2024-07-21 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| AU2018207464B2 (en) | 2017-01-10 | 2020-05-14 | Novartis Ag | Pharmaceutical combination comprising an ALK inhibitor and a SHP2 inhibitor |
| CA3051054A1 (en) | 2017-01-23 | 2018-07-26 | Revolution Medicines, Inc. | Pyridine compounds as allosteric shp2 inhibitors |
| CN110446709B (zh) | 2017-01-23 | 2023-09-12 | 锐新医药公司 | 作为变构shp2抑制剂的二环化合物 |
| US10988466B2 (en) | 2017-03-23 | 2021-04-27 | Jacobio Pharmaceuticals Co., Ltd. | Heterocyclic derivatives useful as SHP2 inhibitors |
| JP2020520988A (ja) | 2017-04-05 | 2020-07-16 | レボリューション メディシンズ インコーポレイテッドＲｅｖｏｌｕｔｉｏｎ Ｍｅｄｉｃｉｎｅｓ，Ｉｎｃ． | タンパク質−タンパク質界面を分析するための方法及び試薬 |
| US20200199102A1 (en) | 2017-04-05 | 2020-06-25 | Revolution Medicines, Inc. | Compounds that participate in cooperative binding and uses thereof |
| US11591336B2 (en) | 2017-05-26 | 2023-02-28 | D. E. Shaw Research, Llc | Substituted pyrazolo[3,4-b]pyrazines as SHP2 phosphatase inhibitors |
| EP3678703A1 (en) | 2017-09-07 | 2020-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| RU2020115095A (ru) | 2017-10-12 | 2021-11-12 | Революшн Медсинз, Инк. | Пиридиновые, пиразиновые и триазиновые соединения в качестве аллостерических ингибиторов shp2 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| MA51845A (fr) | 2018-02-13 | 2020-12-23 | Shanghai Blueray Biopharma Co Ltd | Composé cyclique fusionné à une pyrimidine, son procédé de préparation et son application |
| CN110156786B (zh) | 2018-02-13 | 2022-06-03 | 青煜医药研发(上海)有限公司 | 嘧啶并环化合物及其制备方法和应用 |
| TW201940167A (zh) | 2018-03-21 | 2019-10-16 | 美商新標利亞治療藥物公司 | Shp2抑制劑及其用途 |
| JP2021521155A (ja) | 2018-04-10 | 2021-08-26 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｓｈｐ２阻害剤組成物、癌を処置するための方法、およびｓｈｐ変異を有する対象を特定するための方法 |
| BR112020022201A2 (pt) | 2018-05-01 | 2021-02-02 | Revolution Medicines, Inc. | análogos de rapamicina ligada a c40, c28, e c-32 como inibidores de mtor |
| JP7381492B2 (ja) | 2018-05-01 | 2023-11-15 | レヴォリューション・メディスンズ，インコーポレイテッド | Ｍｔｏｒ阻害剤としてのｃ２６－連結ラパマイシン類似体 |
| WO2020055761A1 (en) | 2018-09-10 | 2020-03-19 | Mirati Therapeutics, Inc. | Combination therapies |
| JP7542538B2 (ja) | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
| JP7377679B2 (ja) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| JP2022520154A (ja) | 2018-12-21 | 2022-03-29 | レボリューション メディシンズ インコーポレイテッド | 協同的結合に関与する化合物及びその使用 |
| CN115873020A (zh) | 2019-11-04 | 2023-03-31 | 锐新医药公司 | Ras抑制剂 |
-
2017
- 2017-07-11 TW TW106123173A patent/TWI806832B/zh active
- 2017-07-11 CN CN202310285469.3A patent/CN116478132A/zh active Pending
- 2017-07-11 IL IL311645A patent/IL311645A/en unknown
- 2017-07-11 EP EP17742609.5A patent/EP3484856B1/en active Active
- 2017-07-11 MA MA045660A patent/MA45660A/fr unknown
- 2017-07-11 IL IL264186A patent/IL264186B2/en unknown
- 2017-07-11 SG SG11201900157RA patent/SG11201900157RA/en unknown
- 2017-07-11 TN TNP/2019/000010A patent/TN2019000010A1/en unknown
- 2017-07-11 CA CA3030167A patent/CA3030167A1/en active Pending
- 2017-07-11 EP EP23209237.9A patent/EP4302834A3/en active Pending
- 2017-07-11 BR BR112019000494-7A patent/BR112019000494A2/pt active Search and Examination
- 2017-07-11 CN CN202310268752.5A patent/CN116478131A/zh active Pending
- 2017-07-11 MX MX2019000548A patent/MX2019000548A/es unknown
- 2017-07-11 TW TW112121134A patent/TW202413340A/zh unknown
- 2017-07-11 PE PE2019000035A patent/PE20190624A1/es unknown
- 2017-07-11 KR KR1020237037794A patent/KR20230156174A/ko active Application Filing
- 2017-07-11 KR KR1020197004088A patent/KR102598895B1/ko active IP Right Grant
- 2017-07-11 JP JP2019522611A patent/JP6916279B2/ja active Active
- 2017-07-11 AU AU2017296289A patent/AU2017296289A1/en not_active Abandoned
- 2017-07-11 CR CR20190063A patent/CR20190063A/es unknown
- 2017-07-11 WO PCT/US2017/041577 patent/WO2018013597A1/en active Application Filing
- 2017-07-11 CN CN201780050842.XA patent/CN109983001B/zh active Active
-
2018
- 2018-12-20 US US16/228,324 patent/US10590090B2/en active Active
-
2019
- 2019-01-08 DO DO2019000005A patent/DOP2019000005A/es unknown
- 2019-01-09 PH PH12019500056A patent/PH12019500056A1/en unknown
- 2019-01-11 MX MX2022007607A patent/MX2022007607A/es unknown
- 2019-01-11 CL CL2019000090A patent/CL2019000090A1/es unknown
- 2019-01-22 CO CONC2019/0000613A patent/CO2019000613A2/es unknown
- 2019-02-12 EC ECSENADI201910079A patent/ECSP19010079A/es unknown
-
2020
- 2020-06-18 US US16/905,884 patent/US11661401B2/en active Active
-
2021
- 2021-07-15 JP JP2021116788A patent/JP7416740B2/ja active Active
- 2021-11-30 AU AU2021277664A patent/AU2021277664B2/en active Active
-
2023
- 2023-03-21 US US18/124,352 patent/US20240116878A1/en active Pending
- 2023-10-13 JP JP2023177195A patent/JP2024009957A/ja active Pending
- 2023-11-16 AU AU2023266357A patent/AU2023266357A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019527728A5 (ja) | ||
| JP2018531274A5 (ja) | 炎症促進性細胞へのマクロファージ分極を改変して癌を治療するための抗ＳＩＲＰａ化合物 | |
| JP2021502386A5 (ja) | ||
| JP2015508103A5 (ja) | ||
| JP2018024670A5 (ja) | ||
| JP2018503663A5 (ja) | ||
| JP2009535462A5 (ja) | ||
| JP2017503000A5 (ja) | ||
| JP2016518328A5 (ja) | ||
| JP2019514955A5 (ja) | ||
| RU2016141934A (ru) | Ингибиторы циклин-зависимой киназы 7 (cdk7) | |
| JP2016006118A5 (ja) | ||
| JP2021502388A5 (ja) | ||
| JP2013537203A5 (ja) | ||
| JP2014511840A5 (ja) | ||
| JP2008500997A5 (ja) | ||
| JP2009545527A5 (ja) | ||
| JP2016505637A5 (ja) | ||
| JP2013502441A5 (ja) | ||
| JP2019516739A5 (ja) | ||
| JP2015508092A5 (ja) | ||
| JP2016531126A5 (ja) | ||
| JP2019535723A5 (ja) | ||
| JP2018534286A5 (ja) | ||
| JP2019519512A5 (ja) |